Syngene grows biopharma manufacturing capabilities

Syngene International, an integrated research, development and manufacturing services organization, has expanded its biomanufacturing capacity by setting up a new microbial current good manufacturing practice (cGMP) facility that is also FDA and European Medicines Agency (EMA) compliant. The company has also increased the capacity of its mammalian cell manufacturing facility to cover end-to-end chemistry, manufacturing and control (CMC) development solutions for its global clients. Both facilities are located at its Biocon Park campus in Bengaluru, India.

The new microbial facility has two fermenters of 200 liter and 500-liter capacity. The microbial center will provide additional integration opportunities with Syngene’s existing discovery and development capabilities; it will also extend service offerings in the GMP manufacturing field of plasmid DNA (pDNA) and mRNA. An additional 2000L single use bioreactor will be added as well.

Company officials expect this expansion to strengthen Syngene’s service offerings for commercial supply, while adding to its existing biopharma manufacturing capabilities.